AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
(From Chemical Business NewsBase - Press Release)
Newly published data show that treatment with 5 mg Actonel (risedronate sodium tablets) daily reduced the risk of spinal fracture in postmenopausal osteoporotic patients at higher risk of fracture because of age or low bone mineral density (BMD) at the hip. In these patients, fracture risk was reduced by 62% and 60% at one year with Actonel compared with placebo. The analysis of combined data from two studies was published in the Feb 2002 issue of the Journal of Clinical Endocrinology and Metabolism, and also shows that the fracture reduction benefits of Actonel in patients at higher risk of fracture were similar to the benefits observed in the overall populations of patients with established osteoporosis. To determine the effect of Actonel on new spinal fractures in patients at high risk of fracture, data were pooled from two randomised, double blind studies (VERT-MN and VERT-NA) in 2457 postmenopausal osteoporotic women treated with placebo or Actonel 5 mg daily. All women received 1000 mg/day calcium and up to 500 IU/day of vitamin D. A post hoc analysis evaluated fracture risk at one year in patients at high risk of fracture, defined in this ...